Fundraising Fox
Adaptimmune
OTC: ADAPYAbingdon, Oxfordshire, US · Founded 2008 · 128 employees on LinkedIn · 6 known investors
Find your way into Adaptimmune
Sign up to see every warm intro you have to Adaptimmune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adaptimmune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Founders & leadership
Adaptimmune was founded in 2008 by James Noble.
JN
James NobleChief Executive Officer
AR
GW
Gavin WoodChief Financial Officer2020–2025He has over thirty years of financial leadership experience, including roles at publicly listed companies on the London and NASDAQ exchanges, and has managed capital raises of approximately $1 billion in equity and debt financing.
WB
William BertrandChief Operating Offcer2017–2025He has held senior executive roles spanning legal, corporate development, regulatory affairs, and business development across pharmaceutical and biotechnology organizations.
JL
John LungerChief Patient Supply Officer2019–2025He brings extensive experience in life sciences operations, pharmaceutical supply chain and manufacturing across cell and gene therapies, small molecules, and biologics, along with background in corporate development and mergers and acquisitions; he holds an MBA from the University of Chicago Booth School of Business and graduated from the United States Naval Academy.
JB
Joanna BrewerChief Scientific Officer
CP
Cintia PiccinaChief Commercial Officer (CCO)2024–2025With more than 20 years of experience in life sciences, she has held leadership roles across biotech and pharmaceutical companies in commercial operations and business development, with expertise in cell and gene therapy, oncology, immunology, and rare diseases.
Board
DM
David MottBoard director
AB
PT
Peter ThompsonBoard director
Investors · 6
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
Eight Roads Ventureslisted by Eight Roads VenturesMumbai · $5M – $30M
How we know: Eight Roads Ventures's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$103.8M disclosed across 1 round · 2014
▶$103.8MraisedOct 2014 · 22 investors · BiotechnologyRule 506(b)
▶$103.8MraisedOct 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MottDirector
- Ali BehbahaniDirector
- Peter ThompsonDirector
- Elliott SigalDirector
- Dr. Jonathan KnowlesDirector
- James NobleExecutive Officer, Director
- Ian LaingDirector
- Offering amount
- $103.8M
- Amount sold
- $103.8M
- Minimum investment
- $1
- First sale
- Sep 2014
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Adaptimmune went on to found or lead other companies.
Related companies · 4
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Massive BioMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Companies working in the same space as Adaptimmune.
Frequently asked questions
- What does Adaptimmune do?
- Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
- Who founded Adaptimmune?
- Adaptimmune was founded by James Noble in 2008.
- Who are Adaptimmune's investors?
- Adaptimmune's investors include Avoro Capital Advisors, Eight Roads Ventures, F-Prime Capital, Foresite Capital, New Enterprise Associates (NEA), Ridgeback Capital.
- How much funding has Adaptimmune raised?
- Adaptimmune has disclosed $103.8M raised across 1 round.
- Where is Adaptimmune headquartered?
- Adaptimmune is headquartered in Abingdon, Oxfordshire, US.